[1]
Katritzky, A.R.; Ramsden, C.A.; Joule, J.A.; Zhdankin, V.V. Handbook of heterocyclic chemistry; Elsevier, 2010.
[4]
Pitasse-Santos, P.; Sueth-Santiago, V.; Lima, M.E. 1, 2, 4-and 1, 3, 4-Oxadiazoles as scaffolds in the development of antiparasitic agents. J. Braz. Chem. Soc., 2018, 29(3), 435-456.
[5]
Nagaraj, C.K.; Niranjan, M.S.; Kiran, S. 1, 3, 4-Oxadiazole: A potent drug candidate with various pharmacological activities. Int. J. Pharm. Pharm. Sci., 2011, 3(3), 9-16.
[9]
Bala, S.; Kamboj, S.; Kumar, A. Heterocyclic 1, 3, 4-oxadiazole compounds with diverse biological activities: A comprehensive review. J. Pharm. Res., 2010, 3(12), 2993-2997.
[10]
Singh, P.; Jangra, P.K. Oxadiazoles: a novel class of anti-convulsant agents. Der Chemica Sinica., 2010, 1(3), 118-123.
[11]
Singh, A.K.; Sahu, V.K.; Yadav, D. Biological activities of 2, 5-di-substituted-1, 3, 4-oxadiazoles. Int. J. Pharm. Sci. Res., 2011, 2(6), 135-147.
[12]
Nimavat, B.; Mohan, S.; Saravanan, J.; Deka, S.; Talukdar, A.; Sahariah, B.J.; Dey, B.K.; Sharma, R.K. Synthesis and characterization of some novel oxadiazoles for in–vitro Anti-inflammatory activity. Int. J. Res. Pharm. Chem., 2012, 2(3), 594-602.
[18]
Sharma, S.; Sharma, P.K.; Kumar, N.; Dudhe, R. A review: oxadiazole their chemistry and pharmacological potentials. Pharma Chem., 2010, 2(4), 253-263.
[34]
James, N.D.; Growcott, J.W. Zibotentan endothelin ETA receptor antagonist oncolytic. Drugs Future, 2009, 34(8), 624-633.
[35]
Brandenberger, H.; Maes, R.A., Eds.; Analytical toxicology for clinical, forensic and pharmaceutical chemists; Walter de Gruyter, 2011.
[58]
Al-Ghorbani, M.; Gouda, M.A.; Baashen, M. A review on synthetic routes of 5-aryl-1, 3, 4-oxadiazoles. Indian J. Heterocycl. Chem., 2019, 29(1), 27-37.
[67]
Lotfi, B; Mustafa, B; Leila, L; Salima, M. Electrocyclization of
semicarbazone; A novel route of green synthesis of 2, 5-
disubstituted-1, 3, 4-oxadiazoles. Int. J. Electrochem. Sci., 2011,
6(1991), 2000.
[82]
Kumar, R.; Abdullah, M.M. Synthesis and anticonvulsant potential of some new 4-[5-substituted-[1, 3, 4] oxadiazole-2-yl]-2-phenylquinolines. Indian J. Heterocycl. Chem., 2019, 29(1), 79-86.
[83]
Joule, J.A. Mills, K Heterocyclic chemistry; John Wiley & Sons, 2008.
[85]
Hemming, K. 1, 2, 4-oxadiazoles. InComprehensive Heterocyclic Chemistry, 2008, III, 243-314. [Elsevier Ltd.
[92]
Kaur, M.; Kaur, M.; Singh, S. A review on anticancer activity of 1, 3, 4-oxadiazole. Int.J.Pharm.Drug Analy, 2018, 6, 499-508.
[96]
Kumar, S. Synthesis and biological activity of 5-substituted-2-amino-1, 3, 4-oxadiazole derivatives. Turk. J. Chem., 2011, 35(1), 99-108.
[98]
Bhardwaj, S.; Parashar, B.; Parashar, N.; Sharma, V.K. Microwave assisted synthesis and pharmacological evaluation of some 1, 3, 4-oxadiazole derivatives. Scholar Research Library. Achieves of App Sci Res., 2011, 3(2), 558-567.
[102]
Salimon, J.; Salih, N.; Hameed, A.; Ibraheem, H.; Yousif, E. Synthesis and antibacterial activity of some new 1, 3, 4-oxadiazole and 1, 3, 4-thiadiazole derivatives. J. Appl. Sci. Res., 2010, 6(7), 866-870.
[103]
Srinivas, K.; Shyamkumar Immadi, S.M.; Dontheboina, G.; Domakonda, A.; Modumpally, A. Anticancer and antimicrobial activity of 1-[(5-substituted-1, 3, 4 oxadiazol-2-yl) methyl]-4-benzylpiperazines. Int. J. Phytopharm., 2010, 1(2)
[109]
Bhat, M.A.; Al-Omar, M.A.; Siddiqui, N. Synthesis, anticonvulsant and neurotoxicity of some novel 1, 3, 4-oxadiazole derivatives of phthalimide. Pharma Chem., 2010, 2(2), 1-0.
[112]
Kaur, V.; Kaur, P.; Goswami, M. Pharmacological activities of oxadiazole derivatives: A review. Eur. J. Biomedical., 2018, 5(5), 211-221.
[116]
Srinivas, S.; Aparna, V. Design, synthesis, biological evaluation and molecular docking studies of novel quinazoline derivatives as GSK-3β inhibitors. World J. Pharm. Pharm. Sci., 2013, 2(6), 5842-5851.